Form 4: Viridian Legal Officer Plans Future Stock Sale
Insider Transaction Report
Viridian Therapeutics' Chief Legal Officer, Jennifer Tousignant, reported a planned sale of 2,272 shares of common stock at $31.16 per share, effective December 31, 2025.
Summary
- Jennifer Tousignant, Chief Legal Officer of Viridian Therapeutics, Inc., reported a transaction involving the disposition of common stock.
- The transaction is a planned sale of 2,272 shares of Viridian Therapeutics common stock.
- The shares are to be sold at a price of $31.16 per share.
- The effective transaction date for this disposition is December 31, 2025.
- The shares being sold were originally acquired under the Issuer's employee stock purchase plan.
- Following this planned transaction, Jennifer Tousignant will beneficially own 0 shares directly.
- This transaction was made pursuant to a Rule 10b5-1 plan, indicating a pre-scheduled sale.
Sentiment
Score: 5
Explanation: A routine insider transaction under a 10b5-1 plan is generally neutral in sentiment. The sale of shares acquired through an ESPP for personal liquidity is a common practice and not typically indicative of specific positive or negative company performance or outlook.
Future Outlook
The filing details a pre-planned disposition of shares under a Rule 10b5-1 plan, scheduled for December 31, 2025. This indicates a future, scheduled event for personal liquidity rather than a change in company strategy.
Industry Context
This is a routine insider transaction filing, common across all industries for executives managing personal portfolios. It does not provide specific insights into broader industry trends or competitive landscape for Viridian Therapeutics.
Related Party Transactions
- The shares disposed of were originally acquired through the Issuer's employee stock purchase plan.
Stakeholder Impact
- Shareholders: The impact is likely minimal due to the relatively small number of shares involved and the pre-planned nature of the transaction under a 10b5-1 plan. It is generally viewed as a neutral event for personal financial management.
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Transaction Date: Planned disposition of 2,272 shares of common stock. |
| 01/02/2026 | Filing Date of the Statement of Changes in Beneficial Ownership. |
Keywords
Viridian Therapeutics, VRDN, Insider Transaction, Form 4, Stock Sale, Jennifer Tousignant, Chief Legal Officer, 10b5-1 Plan, Employee Stock Purchase Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.